Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-12-19
2006-12-19
Maier, Leigh C. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S054000, C514S055000, C514S056000, C514S062000, 60, 60, 60
Reexamination Certificate
active
07151099
ABSTRACT:
Taurolidine and/or taurultam is administered during and after surgical removal of a cancerous tumor to treat abdominal cancer.
REFERENCES:
patent: 5077281 (1991-12-01), Reinmuller
patent: 5176651 (1993-01-01), Allgood et al.
patent: 5262403 (1993-11-01), Nicolson et al.
patent: 5725553 (1998-03-01), Moenning
patent: 5749859 (1998-05-01), Powell
patent: 5763421 (1998-06-01), Caretto et al.
patent: 6479481 (2002-11-01), Stendel et al.
patent: 9530423 (1995-11-01), None
patent: 19606897 (1997-08-01), None
patent: 9200743 (1992-01-01), None
patent: 9518638 (1995-07-01), None
patent: 61000017 (1986-01-01), None
patent: WO 88/05301 (1988-07-01), None
Physicians' Desk Reference, pp. 2034-3036, 1995.
C.A. Jacobi et al., “Peritoneale instillation von Taurolidin und Heparin zur Verhinderung von intraperitonealem Tumorwaschstum und Trokarmetastasen bei laparoskopischen Operationen im Rattenmodell” Langenbecks Arch Chir, vol. 382, No. 4, suppl. 1, Jul. 25, 1997, pp. S31-S36.
Morgan McCourt et al., Taurolidine Inhibits Tumor Cell Growth In Vitro and In Vivo,Annals of Surgical Oncology, Jul. 17, 2000, 685-691, vol. 7, No. 9, Lippencott Williams & Wilkins, Ireland.
Embase abstract of J. Surg. Res. vol. 59, No. 6, pp. 764-771.
Treutner, K. et al “Prevention of postoperative adhesions by single intraperitoneal adhesion” J. Surg. Res. vol. 59, pp. 764-771, 1995.
Braumann, C., et al., “The Influence of Intraoperative Intravenous and Intraperitoneal Application of Taurolidine with Heparin on Subcutaneous and Intraperitoneal Tumor Growth in Laparoscopic Surgery in a Rat Model”,Department of Surgery, Humboldt-University of Berlin, Campus Chartié Mitte, Schumannstr. 20-21, 10098 Berlin, Germany, Apr. 14th and 15th, 2000, 3 pages.
Jacobi, C.A., et al., “Influence of Different Gases and Intraperitoneal Instillation of Antiadherent or Cytotoxic Agents on Peritoneal Tumor Cell Growth and Implantation with Laparoscopic Surgery in a Rat Model”,Surg Endosc, (1999) 13:1021-1025.
Jacobi, C.A., et al., “New Therapeutic Strategies to Avoid Intra-and Extraperitoneal Metastases during Laparoscopy: Results of a Tumor Model in the Rat”,Dig Surg, 1999; 16:393-399.
Jacobi, C.A., et al., “Inhibition of Peritoneal Tumor Cell Growth and Implantation in Laparoscopic Surgery in a Rat Model”,The American Journal of Surgery, (1997) vol. 174, pp. 359-363.
Monson, J.R.T., et al., “Preliminary Evidence that Taurolidine is Anti-neoplastic as well as Anti-endotoxin and Anti-microbial”,Br. J. Surg., A711, vol. 77, No. 6, Jun. 1990.
Monson, J.R.T., et al., “Taurolidine As An Anti-neoplastic Agent: A Previously Undiscovered role?”,Br. J. Surg., 1432, vol. 77, No. 12, Dec. 1990.
Pfirrmann Rolf W.
Redmond H. Paul
Ed. Geistlich Soehne AG fuer Chemische Industrie
Maier Leigh C.
Rothwell Figg Ernst & Manbeck
LandOfFree
Use of taurolidine and/or taurultam for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of taurolidine and/or taurultam for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of taurolidine and/or taurultam for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3676638